Whether the net effect of multikinase/mTOR inhibitor therapy versus manifest arterial hypertension favors the anticancer therapy depends mainly on the severity of hypertension and the effect of antihypertensive treatment and needs to be assessed clinically for each individual patient. The gene discussed is MTOR; the disease is hypertensive disorder.